Drugnews

What clinical evidence did Drugnews report for OBI-992?

As of Drugnews’s October 30, 2026 Taiwan ADC analysis, OBI Pharma’s TROP2-targeting OBI-992 was in early clinical development, with about 117 planned patients across eight U.S. and Taiwan sites. The trial began on June 12, 2024. The article reports partial responses in three patients by December 2025 and describes four payloads per antibody; these are not pivotal efficacy results.

Updated

OBI-992 evidence and study design in the original analysis
MeasureReported resultBasis
Planned enrollmentAbout 117 patientsStudy design, not completed enrollment
Trial footprinteight sitesUnited States and Taiwan
Reported partial responsesthree patientsEarly company-reported observation
Drug-to-antibody ratiofour payloads per antibodyMolecular design, not response rate

The partial-response count has no denominator here and is not an objective response rate or a comparison against another drug.

Sources

Read the full analysis

Taiwan ADCs: Who May Reach Pivotal First? — 2026-10-30